Statement of Changes in Beneficial Ownership (4)
2020年10月21日 - 5:09AM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Haviland Kate |
2. Issuer Name and Ticker or Trading Symbol
Blueprint Medicines Corp
[
BPMC
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) Chief Operating Officer |
(Last)
(First)
(Middle)
C/O BLUEPRINT MEDICINES CORPORATION, 45 SIDNEY STREET |
3. Date of Earliest Transaction
(MM/DD/YYYY)
10/16/2020 |
(Street)
CAMBRIDGE, MA 02139
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock | 10/16/2020 | | M(1) | | 13334 | A | $36.05 | 56172 | D | |
Common Stock | 10/16/2020 | | S(1) | | 3009 | D | $102.53 (2) | 53163 | D | |
Common Stock | 10/16/2020 | | S(1) | | 3125 | D | $101.56 (3) | 50038 | D | |
Common Stock | 10/16/2020 | | S(1) | | 7200 | D | $100.55 (4) | 42838 | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Stock Option (Right to Buy) | $36.05 | 10/16/2020 | | M (1) | | | 13334 | (5) | 2/16/2027 | Common Stock | 13334 | $0 | 5000 | D | |
Explanation of Responses: |
(1) | Effected pursuant to a trading plan adopted on April 19, 2019 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. |
(2) | The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $102.40 to $102.73 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2) through (4) of this form 4. |
(3) | The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $101.28 to $102.24 per share. |
(4) | The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.24 to $101.235 per share. |
(5) | This option was granted on February 16, 2017. This option vested with respect to 1/48th of the shares underlying the option on March 16, 2017 and as to an additional 1/48th of the shares underlying the option each month thereafter. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Haviland Kate C/O BLUEPRINT MEDICINES CORPORATION 45 SIDNEY STREET CAMBRIDGE, MA 02139 |
|
| Chief Operating Officer |
|
Signatures
|
/s/ Christopher Frankenfield, Attorney-in-Fact | | 10/20/2020 |
**Signature of Reporting Person | Date |
Blueprint Medicines (NASDAQ:BPMC)
過去 株価チャート
から 7 2024 まで 8 2024
Blueprint Medicines (NASDAQ:BPMC)
過去 株価チャート
から 8 2023 まで 8 2024